Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
DRUG

Lasofoxifene

Estrogen receptor antagonist antineoplastic agent

DRUG

Fulvestrant

Estrogen receptor antagonist antineoplastic agent

Trial Locations (51)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

15232

UPMC Hillman Cancer Center, Pittsburgh

21702

FMH James M Stockman Cancer Institute (JIT), Frederick

23601

Peninsula Cancer Institute, Newport News

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

32224

Mayo Clinic Florida, Jacksonville

32308

Florida Cancer Specialists, Tallahassee

33176

Miami Cancer Institute, Miami

33880

The Bond Clinic Cancer & Research Center., Winter Haven

34474

Ocala Oncology Center (JIT), Ocala

37203

Tennessee Oncology/SCRI, Nashville

37404

Tennessee Oncology Chattanooga, Chattanooga

38138

West Cancer Center, Germantown

39401

Hattiesburg Clinic Hematology/Oncology, Hattiesburg

40202

University of Louisville / James Graham Brown Cancer Center, Louisville

43210

The Ohio State University - Comprehensive Cancer Center, Columbus

43221

Ohio Health (JIT), Columbus

45220

TriHealth Cancer Institute, Cincinnati

46601

Beacon Health (JIT), South Bend

49100

Rabin Medical Center, Petah Tikva

55902

Mayo Clinic, Rochester

57104

Sanford Cancer Center (JIT), Sioux Falls

60611

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

60637

University of Chicago, Chicago

61615

Illinois Cancer Care (JIT), Peoria

61801

Carle Cancer Center, Urbana

63110

Washington University School of Medicine, St Louis

64111

Saint Luke's Cancer Institute, Kansas City

64132

HCA Midwest Health, Kansas City

75230

Mary Crowley Cancer Research (JIT), Dallas

77024

Oncology Consultants (JIT), Houston

80501

Rocky Mountain Cancer Centers, Longmont

84101

Soroka University Medical Center, Beersheba

84102

Utah Cancer Specialists (JIT), Salt Lake City

85054

Mayo Clinic Arizona, Phoenix

85364

Yuma Regional Medical Center (JIT), Yuma

89128

Comprehensive Cancer Centers of Nevada (JIT), Las Vegas

91010

City of Hope Comprehensive Cancer, Duarte

92708

Compassionate Care Research Group, Fountain Valley

94115

UCSF Cancer Center, San Francisco

96813

Hawaii Cancer Care (JIT), Honolulu

9112001

Hadassah Ein Kerem Medical Center, Jerusalem

52656021

Sheba Medical Center, Ramat Gan

07203

New Jersey Cancer Care and Blood Disorders (JIT), Belleville

07932

Summit Medical Group (JIT), Florham Park

K1H8L6

The Ottawa Hospital, Ottawa

M4N3M5

Sunnybrook Health Sciences Center, Toronto

G7H5H6

CIUSSS de Saguenay-Lac-Saint Jean, Chicoutimi

H3T1E2

Jewish General Hospital, Montreal

H4A3J1

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

Linical Accelovance Group

UNKNOWN

lead

Sermonix Pharmaceuticals Inc.

INDUSTRY

NCT03781063 - Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Biotech Hunter | Biotech Hunter